Acotiamide-d4

• Description:

  Acotiamide-d4 (Z-338 (free base) -d4) is deuterium labeled Acotiamide. Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory[1][2][3].

• Product Name Alternative:

  Z-338 (free base) -d4; YM443 (free base) -d4

• UNSPSC:

  12352005

• Target:

  Cholinesterase (ChE) ; Isotope-Labeled Compounds

• Related Pathways:

  Neuronal Signaling; Others

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Smiles:

  O=C (NC ([2H]) (C ([2H]) (N (C (C) C) C (C) C) [2H]) [2H]) C1=CSC (NC (C2=CC (OC) =C (C=C2O) OC) =O) =N1

• Molecular Formula:

  C21H26D4N4O5S

• Molecular Weight:

  454.58

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kazuyoshi Y oshii, et al. Physiologically-Based Pharmacokinetic and Pharmacodynamic Modeling for the Inhibition of Acetylcholinesterase by Acotiamide, A Novel Gastroprokinetic Agent for the Treatment of Functional Dyspepsia, in Rat Stomach. Pharmaceutical Research, 33 (2), 292–300.|[3]Hiroshi Yamawaki, et al. Acotiamide attenuates central urocortin 2-induced intestinal inflammatory responses, and urocortin 2 treatment reduces TNF-α productions in LPS-stimulated macrophage cell lines. Neurogastroenterol Motil. 2020 Aug;32 (8) :e13813.|[4]Matsunaga Y, Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011 Mar;336 (3) :791-800.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported